Dalpiciclib

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Dalpiciclib is a drug for the treatment of various forms of cancer. In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy. Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.

Dalpiciclib is a drug for the treatment of various forms of cancer. In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy. Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1357571692 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.